View Item 

Show simple item record

Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic Effects
dc.contributor.authorVeltri, Salvatore
dc.contributor.authorSmith, John W.
dc.date.accessioned2017-12-15T16:46:33Z
dc.date.available2017-12-15T16:46:33Z
dc.date.issued1996-08
dc.identifier.citationVeltri, Salvatore; Smith, John W. (1996). "Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic Effects." The Oncologist 1(4): 190-200.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139898
dc.publisherWiley Periodicals, Inc.
dc.publisherAlphaMed Press
dc.subject.otherHematopoietic effects
dc.subject.otherInterleukin 1
dc.subject.otherNeoplasms
dc.subject.otherReview
dc.subject.otherClinical trials
dc.subject.otherToxicity
dc.subject.otherAntitumor effects
dc.titleInterleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic Effects
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumThe University of Michigan Medical Center, Department of Internal Medicine, Division of Hematology/Oncology, Ann Arbor, Michigan, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139898/1/onco0190.pdf
dc.identifier.doi10.1634/theoncologist.1-4-190
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceJ Vredenburgh, M Ross, J Kurtzberg et al. Phase I trial of interleukin 1β (IL‐1β) following high‐dose chemotherapy and autologous bone marrow transplantation (ABMT). Blood 1991; 78: 6a.
dc.identifier.citedreferenceS Vadhan‐Raj, A Kudelka, L Garrison et al. Effects of interleukin 1α on carboplatin‐induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 1994; 12: 707 – 714.
dc.identifier.citedreferenceL Schuchter, D Neuberg, M Atkins et al. A phase I study of interleukin 1 alpha and high‐dose cyclophosphamide in patients with advanced cancer. Proc ASCO 1994; 13: 133a.
dc.identifier.citedreferenceMA Bookman, DA Caron, WM Hogan et al. Phase‐1 evaluation of dose‐intense chemotherapy with interleukin 1α (IL‐1α) for gynecologic malignancies. Proc ASCO 1993; 12: 868a.
dc.identifier.citedreferenceRH Wheeler, RF Meredith, MN Saleh et al. A phase II trial of IL‐1 plus radioimmunotherapy (RIT) in patients with metastatic colon cancer. Proc ASCO 1994; 13: 295a.
dc.identifier.citedreferenceWH Wilson, G Bryant, V Jain et al. Phase I study of infusional interleukin 1α (IL‐1) with ifosfamide (I), CBDCA (C), and etoposide (E) (ICE) and autologous bone marrow transplant (BMT). Proc Am Soc Clin Oncol 1992; 11: 335a.
dc.identifier.citedreferenceWH Wilson, G Bryant, M Fox et al. Interleukin 1α administered before high‐dose isosfamide (I), CBDCA (C), and etoposide (E) (ICE) with autologous bone marrow rescue shortens neutrophil recovery: a phase I/II study. Proc ASCO 1993; 12: 937a.
dc.identifier.citedreferenceDJ Weisdorf, E Katsanis, C Verfaillie et al. Interleukin 1α after autologous transplantation for lymphoma/Hodgkin’s disease: clinical and hematologic effects. Blood 1992; 80: 1321a.
dc.identifier.citedreferenceD Weisdorf, E Katsanis, C Verfaillie et al. Interleukin 1α administered after autologous transplantation: phase I/II clinical trial. Blood 1994; 84: 2044 – 2049.
dc.identifier.citedreferenceJ Nemunaitis, CD Buckner, O Press et al. Phase I trial with interleukin 1β (IL‐1β) in patients undergoing autologous bone marrow transplantation (ABMT) for acute myelogenous leukemia (AML). Blood 1991; 78: 8a.
dc.identifier.citedreferenceJ Nemunaitis, FR Applebaum, K Lilleby et al. Phase I study with recombinant human interleukin 1β in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood 1994; 83: 3473 – 3479.
dc.identifier.citedreferenceD Beasley, JH Schwartz, BM Brenner. Interleukin 1 induces prolonged L‐arginine‐dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991; 87: 602 – 608.
dc.identifier.citedreferenceRG Kilbourn, SS Gross, A Jubran et al. N G ‐methyl‐L‐arginine inhibits tumor necrosis factor‐induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990; 87: 3629 – 3632.
dc.identifier.citedreferenceRG Kilbourn, SS Gross, JA Lodato et al. Inhibition of interleukin 1‐alpha‐induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin 1‐alpha‐induced hypotension by N‐omega‐amino‐L‐arginine. J Natl Cancer Inst 1992; 84: 1008 – 1016.
dc.identifier.citedreferenceJ Crawford, H Ozer, R Stoller et al. Reduction by granulocyte colony‐stimulating factor of fever and neutropenia induced by chemotherapy in patients with small‐cell lung cancer. N Engl J Med 1991; 325: 164 – 170.
dc.identifier.citedreferenceJ Nemunaitis, SN Rabinowe, JW Singer et al. Recombinant granulocyte‐macrophage colony‐stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773 – 1778.
dc.identifier.citedreferenceE Bruno, R Hoffman. Effect of interleukin 6 on in vitro human megakaryocytopoiesis: its interaction with other cytokines. Exp Hematol 1989; 17: 1038 – 1041.
dc.identifier.citedreferenceRA Briddell, JE Brandt, TB Leemhuis et al. Role of cytokines in sustaining long‐term human megakaryocytopoiesis in vitro. Blood 1994; 79: 332 – 337.
dc.identifier.citedreferenceK Ikebuchi, JN Ihle, Y Hirai et al. Synergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by interleukin 1, interleukin 6, and granulocyte‐colony stimulating factor. Blood 1988; 72: 2007 – 2014.
dc.identifier.citedreferenceRL Hornung, DL Longo. Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high‐dose cyclophosphamide therapy. Blood 1992; 80: 77 – 83.
dc.identifier.citedreferenceMS Gordon, R Hoffman. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood 1992; 80: 302 – 307.
dc.identifier.citedreferenceS Lok, K Kaushansky, RD Holly et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369 ( 6481 ): 565 – 568.
dc.identifier.citedreferenceK Kaushansky, S Lok, RD Holly et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c‐Mpl ligand thrombopoietin. Nature 1994; 369 ( 6481 ): 568 – 571.
dc.identifier.citedreferenceE Atkins. The pathogenesis of fever. Physiol Rev 1960; 40: 580 – 646.
dc.identifier.citedreferenceCA Dinarello. Biology of interleukin 1: Federation of American Societies for Experimental Biology. Biology 1988; 2: 108 – 115.
dc.identifier.citedreferencePT Lomedico, CP Gubler, CP Hellman et al. Cloning and expression of murine interleukin 1 cDNA in Eschericha coli. Nature 1984; 312: 458 – 462.
dc.identifier.citedreferenceSK Dower, SR Kronheim, CJ March et al. The cell surface receptors for interleukin 1 alpha and interleukin 1 beta are identical. Nature 1986; 324: 266 – 269.
dc.identifier.citedreferenceS Nakamura, S Kashimoto, F Kajikawa et al. Combination effect of recombinant human interleukin 1α with antitumor drugs on syngeneic tumors in mice. Cancer Res 1991; 51: 215 – 221.
dc.identifier.citedreferenceK Onozaki, K Matsushima, BB Aggarwal et al. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 1985; 135: 3962 – 3968.
dc.identifier.citedreferenceWL Crump III, LB Owen‐Schaub, EA Grimm. Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine activated killer cells. Cancer Res 1989; 49: 149 – 153.
dc.identifier.citedreferenceJ Herman, CA Dinarello, MC Kew et al. The role of interleukin 1 (IL‐1) in tumor NK cell interactions. Correction of defective NK cell activity in cancer patients by treating target cells with IL‐1. J Immunol 1985; 135: 2882 – 2886.
dc.identifier.citedreferenceU Yamashita, F Shirakawa. Restoration of impaired T cell functions in tumor‐bearing mice by the administration of interleukin 1. Gann 1987; 78: 270 – 278.
dc.identifier.citedreferenceME Neville. Antitumor effects of interleukin 1β: inhibition of angiogenesis. Proc Annu Meet Assoc Cancer Res 1990; 31: 1741a.
dc.identifier.citedreferenceR Philip, LB Epstein. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma‐interferon and interleukin 1. Nature 1986; 323: 86 – 89.
dc.identifier.citedreferenceS Nakai, Y Hirai. The therapeutic potential of interleukin 1 beta in the treatment of chemotherapy or radiation induced myelosuppression and in tumor therapy. Biotherapy 1989; 1: 339 – 354.
dc.identifier.citedreferenceR Neta, S Douches, J Oppenheim. Interleukin 1 is a radioprotector. J Immunol 1987; 136: 2483 – 2488.
dc.identifier.citedreferenceJ Laver, M Abboude, C Gasparetto et al. Effects of IL‐1 on hematopoietic progenitors after myelosuppressive chemotherapy. Biotherapy 1989; 1: 293 – 300.
dc.identifier.citedreferenceY Ozaki, T Ohashi, A Minami et al. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin 1α. Infect Immun 1987; 55: 1436 – 1440.
dc.identifier.citedreferenceJW Smith II, WJ Urba, BD Curti et al. The toxic and hematologic effects of interleukin 1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10: 1141 – 1152.
dc.identifier.citedreferenceJ Crown, A Jakubowski, N Kemeny et al. A phase I trial of recombinant human interleukin 1β alone and in combination with myelosuppressive doses of 5‐fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78: 1420 – 1427.
dc.identifier.citedreferenceS Okusawa, JA Gelfand, T Ikejima et al. Interleukin 1 induces a shock‐like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162 – 1172.
dc.identifier.citedreferenceJW Smith II, WJ Urba, R Steis et al. Phase II trial of interleukin 1 alpha (IL‐1α) in combination with indomethacin (IND) in melanoma patients (pts). Proc ASCO 1991; 10: 705a.
dc.identifier.citedreferenceR Steis, JW Smith II, J Janik et al. Phase I study of recombinant IL‐1 beta (Syntex). Proc ASCO 1991; 10: 211a.
dc.identifier.citedreferenceD Dennis, S Chachoua, D Caron et al. Biologic activity of interleukin 1 (IL‐1) alpha in patients with refractory malignancies. Proc ASCO 1992; 11: 830a.
dc.identifier.citedreferenceL Kanz, R Birken, W Brugger et al. Biological activities of subcutaneous (s.c.) rhIL‐1β in cancer patients. Blood 1992; 80: 357a.
dc.identifier.citedreferenceJE Janik, JW Smith II, WJ Urba et al. Phase I trial of intratumoral interleukin 1 alpha (IL‐1α). “Melanoma and Biology of the Neural Crest.” Keystone Symposia, Taos, NM, 1992.
dc.identifier.citedreferenceTM Lestingi, NJ Vogelzang, JM Richards et al. Phase I trial of recombinant interleukin 1α (IL‐1) and recombinant interleukin 2 (IL‐2). Proc ASCO 1993; 12: 976a.
dc.identifier.citedreferencePL Triozzi, JA Kim, EW Martin et al. Phase I trial of escalating doses of Interleukin 1β in combination with a fixed dose of Interleukin 2. J Clin Oncol 1995; 13: 482 – 489.
dc.identifier.citedreferenceHF Starnes, G Hartman, F Torti et al. Recombinant human interleukin 1β (IL‐1β) has anti‐tumor activity and acceptable toxicity in metastatic malignant melanoma. Proc ASCO 1991; 10: 292a.
dc.identifier.citedreferenceJE Janik, LL Miller, DL Longo et al. Phase II trial of Interleukin 1α and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst 1996; 88: 44 – 49.
dc.identifier.citedreferenceBG Redman, YC Abubaker, T Chou et al. Phase II trial of recombinant interleukin 1β in patients with metastatic renal cell carcinoma. J Immunother 1994; 16: 211 – 215.
dc.identifier.citedreferenceWE Fibbe, J van Damme, A Billiau et al. Interleukin 1 induces human marrow stromal cells in long‐term culture to produce granulocyte colony‐stimulating factor and macrophagecolony‐stimulating factor. Blood 1988; 71: 430 – 435.
dc.identifier.citedreferenceG Tosato, KD Jones. Interleukin 1 induces interleukin 6 production in peripheral blood monocytes. Blood 1990; 75: 1305 – 1310.
dc.identifier.citedreferenceMAS Moore. Clinical implications of positive and negative hematopoietic stem cell regulators (Review: Stratton Lecture 1990). Blood 1991; 78: 1 – 19.
dc.identifier.citedreferenceCM Dubois, FW Ruscetti, JR Keller et al. In vivo interleukin 1 (IL‐1) administration indirectly promotes type II IL‐1 receptor expression on hematopoietic bone marrow cells: novel mechanism for the hematopoietic effects of IL‐1. Blood 1991; 78: 2841 – 2847.
dc.identifier.citedreferenceMP Castelli, PL Black, M Schneider et al. Protective, restorative, and therapeutic properties of recombinant human IL‐1 in rodent models. J Immunol 1988; 140: 3830 – 3837.
dc.identifier.citedreferenceH Futami, R Jansen, MJ MacPhee et al. Chemoprotective effects of recombinant human IL‐1α in cyclophosphamide‐treated normal and tumor‐bearing mice. J Immunol 1990; 145: 4121 – 4130.
dc.identifier.citedreferenceJW Smith II, DL Longo, WG Alvord et al. The effects of treatment with interleukin 1α on platelet recovery after high‐dose carboplatin. N Engl J Med 1993; 328: 756 – 761.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0190.pdf
Size:
66.42KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.